

Enrique Colado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1761232/publications.pdf>

Version: 2024-02-01

55
papers

2,313
citations

361413

20
h-index

214800

47
g-index

66
all docs

66
docs citations

66
times ranked

4600
citing authors

#	ARTICLE	IF	CITATIONS
1	Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 272-282.	1.5	5
2	Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia. <i>Oncolmmunology</i> , 2021, 10, 1897294.	4.6	6
3	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.	7.2	31
4	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	4.6	39
5	Immunologic characterization of COVID-19 patients with hematological cancer. <i>Haematologica</i> , 2021, 106, 1457-1460.	3.5	13
6	Development of an algorithm for the identification of leukemic hematolymphoid neoplasms in Primary Care patients. <i>Diagnosis</i> , 2021, 8, 239-247.	1.9	0
7	Expression of CD47 antigen in Reedâ€“Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 782-785.	2.4	9
8	Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 13-15.	1.4	1
9	Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment. <i>Nucleic Acids Research</i> , 2019, 47, 5016-5037.	14.5	23
10	Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world. <i>Leukemia Research</i> , 2019, 79, 69-74.	0.8	3
11	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 576-586.	3.5	40
12	Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation. <i>Blood</i> , 2019, 134, 2687-2687.	1.4	0
13	The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 847-847.	1.4	0
14	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. <i>Modern Pathology</i> , 2018, 31, 1318-1331.	5.5	9
15	Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2018, 32, 645-653.	7.2	91
16	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2318-2326.	1.3	5
17	Prognostic Value of Minimal Residual Disease before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5733-5733.	1.4	0
18	Effects of Estrogen and Phytoestrogen Treatment on an In Vitro Model of Recurrent Stroke on HT22 Neuronal Cell Line. <i>Cellular and Molecular Neurobiology</i> , 2017, 37, 405-416.	3.3	20

#	ARTICLE	IF	CITATIONS
19	The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment. <i>Annals of Hematology</i> , 2017, 96, 1833-1840.	1.8	16
20	Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 361-370.	1.5	19
21	Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. <i>Oncotarget</i> , 2017, 8, 31959-31976.	1.8	39
22	Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 278.e1-278.e7.	0.2	7
23	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 2122-2130.	1.4	260
24	MMP-25 Metalloprotease Regulates Innate Immune Response through NF- κ B Signaling. <i>Journal of Immunology</i> , 2016, 197, 296-302.	0.8	34
25	Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling. <i>Nature Medicine</i> , 2016, 22, 91-96.	30.7	37
26	Clinical Impact of the Quantitative Subclonal Architecture in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2024-2024.	1.4	0
27	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015, 526, 519-524.	27.8	749
28	Mutations in the Toll-like receptor/MYD88 pathway in young (≥ 50 years) CLL patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S203.	0.4	0
29	Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 4138-4138.	1.4	1
30	Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7061-7061.	1.6	0
31	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2014, 38, 551-556.	0.8	11
32	Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). <i>Leukemia and Lymphoma</i> , 2014, 55, 1007-1012.	1.3	20
33	Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. <i>Blood</i> , 2014, 124, 1300-1303.	1.4	67
34	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014, 123, 3790-3796.	1.4	97
35	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. <i>Haematologica</i> , 2014, 99, e231-e234.	3.5	33
36	Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis. <i>Leukemia</i> , 2013, 27, 2149-2156.	7.2	11

#	ARTICLE	IF	CITATIONS
37	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. <i>Leukemia</i> , 2013, 27, 1100-1106.	7.2	167
38	DNA Methylation Dynamics in Blood after Hematopoietic Cell Transplant. <i>PLoS ONE</i> , 2013, 8, e56931.	2.5	24
39	ADAMTS-12 Metalloprotease Is Necessary for Normal Inflammatory Response. <i>Journal of Biological Chemistry</i> , 2012, 287, 39554-39563.	3.4	38
40	MMP-8 Deficiency Increases TLR/RAGE Ligands S100A8 and S100A9 and Exacerbates Lung Inflammation during Endotoxemia. <i>PLoS ONE</i> , 2012, 7, e39940.	2.5	19
41	Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 257-269.	1.8	7
42	Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators. <i>Blood</i> , 2012, 120, 3593-3593.	1.4	3
43	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , 2011, 96, 687-695.	3.5	13
44	Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. <i>American Journal of Hematology</i> , 2010, 85, 290-293.	4.1	2
45	An individualized preoperative blood saving protocol can increase preoperative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. <i>Transfusion Medicine</i> , 2009, 19, 35-42.	1.1	69
46	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. <i>Leukemia</i> , 2009, 23, 2265-2274.	7.2	58
47	Comparison Between Lymphoglobuline- and Thymoglobuline-Based Immunosuppressive Therapy as First-Line Treatment for Patients with Aplastic Anemia.. <i>Blood</i> , 2009, 114, 3194-3194.	1.4	15
48	Zalypsis Possess Potent Antileukemic Effect through the Induction of a DNA Damage Response, Independently of the p53 Status.. <i>Blood</i> , 2009, 114, 3792-3792.	1.4	0
49	Should prophylactic granulocyte colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?. <i>British Journal of Haematology</i> , 2008, 140, 324-326.	2.5	16
50	Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1163-1171.	2.0	85
51	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. <i>Haematologica</i> , 2008, 93, 57-66.	3.5	56
52	VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients. <i>Blood</i> , 2008, 112, 3694-3694.	1.4	1
53	Panobinostat (LBH589) a Promising New Partner for Combination with Doxorubicin in Acute Myeloid Leukemia.. <i>Blood</i> , 2008, 112, 1638-1638.	1.4	16
54	Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells.. <i>Blood</i> , 2006, 108, 1989-1989.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Fludarabine and Busuphan (Flu-Bu) as Reduced Intensity-Conditioning (RIC) Regimen in HLA-Identical Sibling Allogeneic Hematopoietic Stem Transplantation (Allo-SCT) for Myeloid Malignancies. Results of a Prospective Multicenter Study.. Blood, 2006, 108, 5363-5363.	1.4	0